BFC Planning’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
BFC Planning's NBIX Position: Q3 2026 in Review
BFC Planning increased its Neurocrine Biosciences (NBIX) stake by 1.4% in Q3 2026, buying an estimated $482 and bringing the position to 220 shares worth $31.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1796.
BFC Planning first reported a position in NBIX in Q3 2024 and has held it in 9 quarters since. The position peaked at $36.6K in Q2 2026. 661 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- BFC Planning held 220 shares of Neurocrine Biosciences worth $31.2K as of Q3 2026.
- BFC Planning bought 3 Neurocrine Biosciences shares in Q3 2026, an estimated $482.
- Neurocrine Biosciences made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #1796 holding.
- BFC Planning first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 9 quarters since.
- BFC Planning's Neurocrine Biosciences position peaked at $36.6K in Q2 2026.
- 661 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.